[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"airway-inflammation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:airway-inflammation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100601896","cost-effective-air-filtration-intervention-in-low-income-housing-to-reduce-asthma-morbidity-100601896",false,"NCT07116460","Cost Effective Air Filtration Intervention in Low-Income Housing to Reduce Asthma Morbidity","Cost Effective Air Filtration Intervention and Particulate Matter Monitoring in Low-Income Housing to Reduce Asthma Morbidity","Inclusion Criteria:\n\n* Age 7-18 years\n* Asthma symptoms in the past 4 weeks\n* Resident in lower-income housing in NYC Northern Manhattan and South Bronx\n\nExclusion Criteria:\n\n* Inability to successfully perform spirometry maneuver or FeNO test\n* Family planning to move in the next year","ALL","7 Years","18 Years",{"count":20,"type":21},55,"ESTIMATED","INTERVENTIONAL",[24],"NA","This project will investigate the effectiveness of HEPA air cleaners in reducing indoor air pollution and improving asthma morbidity in children living in East Harlem, New York City (NYC). The study will be conducted over a 2-year period.\n\nColumbia University and Little Sisters of the Assumption Family Health Service (LSAFHS) will conduct an intervention study to evaluate the efficacy of using a cost-effective high-capacity high efficiency particulate air (HEPA) filter air cleaner to reduce airborne particulate matter (PM) in the homes of children with asthma and to reduce their asthma morbidity. The study will take place in East Harlem, a low-income neighborhood with high asthma prevalence. It will build on findings from prior Housing and Urban Development Lead and Healthy Homes Technical Studies (HUD LHHTS)-funded research, the experience of LSAFHS installing air cleaners in the homes of asthmatic children, and recent findings demonstrating the effectiveness of home air cleaners in reducing asthma morbidity. The investigators hypothesize that the cost-effective single air cleaner will substantially reduce PM exposure in the homes of asthmatic children and reduce airway inflammation and asthma morbidity. This study will use cutting-edge air sampling technology to continuously quantify and characterize indoor air pollutants in the home for one year, verify and incentivize compliance, and conduct repeated exhaled nitric oxide and pulmonary function tests before and throughout the year after the intervention. This cost-effective intervention can be easily and quickly implemented in homes in low-income, urban communities and easily transferred between homes if families move.",[27,28,29],"Asthma Attack","Lung Function","Airway Inflammation",[31,32,33,34,35,36,37],"asthma","air cleaner","particulate matter","pm2.5","lung function","airway inflammation","children","RECRUITING","2026-05-29",{"date":41,"type":42},"2026-06-02","ACTUAL",{"date":44,"type":42},"2026-01-30",{"date":46,"type":21},"2028-04",{"name":48,"class":49},"Columbia University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":50},"100631976","can-astaxanthin-help-manage-asthma-in-polluted-areas-100631976","NCT07507682","Can Astaxanthin Help Manage Asthma in POlluted Areas?","Investigating Astaxanthin as a Novel Therapy for Asthma Management in Polluted Environments","Inclusion Criteria:\n\n* Adults 18+ y\n* Confirmed clinical diagnosis of mild-to-moderate asthma, defined as:\n\n  * A physician diagnosed asthma condition consistent with BTS\u002FNICE\u002FSIGN (2024)\n  * Asthma managed at GINA (2024) step 1-3 therapy level, with stable maintenance treatment for ≥4 weeks prior to enrolment\n  * No asthma exacerbation requiring systemic corticosteroids within the preceding 6-8 weeks\n\n(those with suspected Asthma will be invited to a familiarisation and eligibility session where they will have clinical investigations to assess for asthma and thus be included or excluded)\n\n* Ability to demonstrate acceptable and repeatable spirometry in accordance with ATS\u002FERS standards\n* Willing to refrain from antioxidant and anti-inflammatory supplementation (e.g. Omega-3, turmeric, NSAID supplements) for the duration of the study\n* Not consuming high dietary ASTX sources (e.g., frequent salmonid or crustacean intake), assessed at screening\n* non-smoking and non-vaping\n* Able and willing to take daily study capsules and attend all required visits\n* Able and willing to complete home monitoring, including peak flow, air-quality monitoring, and questionnaires\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Current smokers or vapers which is associated with chronic airway remodelling, reduce hyperresponsiveness to bronchodilators, and increased neutrophilic inflammation, which can obscure the true effects of asthma-target interventions\n* Respiratory tract infection within the preceding 4 weeks\n* Pregnant or lactating individuals\n* Presence of significant co-morbidities, including CVD or autoimmune or systemic inflammatory diseases\n* Renal or gastrointestinal disorders that may affect astaxanthin absorption and metabolism\n* Known allergy or hypersensitivity to ASTX or any components of the study supplement\n* History of current evidence of alcohol or substance abuse\n* Participation in another interventional drug or supplement study within the preceding 3 months\n* Use of medicines with a narrow therapeutic index where supplement interactions may pose risk (e.g., ciclosporin\u002Ftacrolimus, warfarin), assessed by investigator\n* Other significant chronic respiratory disease (e.g., COPD, bronchiectasis)",true,{"count":60,"type":21},25,[24],"This study will test whether astaxanthin, a naturally occurring antioxidant supplement, can improve lung function, reduce airway inflammation, and improve asthma control in adults with mild-to-moderate asthma. Participants will receive astaxanthin and placebo in random order in a double-blind crossover design. Each treatment period lasts 4 weeks and is separated by a 3-week washout period. The study also measures indoor and personal air pollution exposure to examine whether pollution influences asthma symptoms, airway responsiveness, and response to treatment. Exploratory thoracic bioelectrical impedance spectroscopy will be assessed alongside standard respiratory tests.",[64,29,65],"Asthma (Diagnosis)","Airway Hyperresponsiveness",[67,68,69,70,71,72,73],"Astaxanthin","Mild-to-Moderate Asthma","Air Pollution","FeNO","Hypertonic Saline Challenge","Impulse Oscillometry","Thoracic Bioelectrical Impedance Spectroscopy","2026-03-27",{"date":76,"type":42},"2026-04-02",{"date":78,"type":21},"2026-05-15",{"date":80,"type":21},"2026-07-20",{"name":82,"class":49},"Middlesex University",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":58,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":100,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":50},"100630896","immune-status-and-disease-control-of-inflammatory-airway-diseases-100630896","NCT07493629","Immune Status and Disease Control of Inflammatory Airway Diseases","Association Between Immune Status and Disease Control in Patients With Inflammatory Airway Diseases","ISDC-IAD","Inclusion Criteria\n\n1. Age ≥18 years (≥40 years for COPD patients).\n2. Clinical diagnosis of asthma, ABPA, bronchiectasis, OSAS, or COPD according to established criteria.\n3. PRISm patients (post-BD FEV1\u002FFVC ≥70% and FEV1 \\\u003C80% predicted)\n4. Smoking controls: ≥10 pack-years, normal lung function, no chronic respiratory symptoms.\n5. Healthy controls: normal lung function, FeNO \\\u003C20 ppb, total IgE \\\u003C100 IU\u002FmL, no chronic disease, smoking \\\u003C10 pack-years, no immunosuppressant use within 3 months.\n\nExclusion Criteria\n\n1. Patients with severe respiratory diseases other than those included in the study, such as pulmonary embolism, pneumothorax, pulmonary hypertension, interstitial lung disease, or active lung cancer.\n2. Patients with severe systemic diseases that may interfere with study completion, such as myocardial infarction, severe arrhythmia, hepatic insufficiency, renal insufficiency, hematological disorders, or malignancy.\n3. Patients with an acute exacerbation within 4 weeks before enrollment, or systemic use of antibiotics, antifungal drugs, immunosuppressive agents, cytotoxic agents, or corticosteroids (except for long-term maintenance therapy)\n4. Pregnant or lactating women.\n5. Patients with poor compliance as judged by the investigators.\n6. Subjects currently participating in other clinical studies.",{"count":92,"type":21},200,"OBSERVATIONAL","The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand:\n\n1.Whether specific immune cell patterns in the blood are linked to how severe the disease is or how well it is controlled.\n\nParticipants will:\n\n1. Answer questions about their health and symptoms.\n2. Give blood samples\n3. Have lung function tests and other standard check-ups.\n4. share sleep study results. We will compare people with airway diseases to healthy volunteers to see how their immune systems differ.",[29,96,64,97,98,99],"Chronic Obstructive Pulmonary Disease (COPD)","Bronchiectasis","OSAS (Obstructive Sleep Apneas Syndrome)","Allergic Bronchopulmonary Aspergillosis (ABPA)",[101,102,103,104,105],"Airway Inflammatory Diseases","Immunophenotyping","Metabolomics","Cytometry by Time-of-Flight","High-dimensional immune profiling","2026-03-23",{"date":108,"type":42},"2026-03-25",{"date":110,"type":42},"2025-08-01",{"date":112,"type":21},"2026-08-01",{"name":114,"class":115},"First Affiliated Hospital of Ningbo University","NETWORK"]